secwatch.observer — SEC 8-K summary
======================================

Issuer:     GALECTIN THERAPEUTICS INC (GALT)
CIK:        0001133416
Form:       8-K
Filed at:   2025-11-10T23:59:59+00:00
Accession:  0001140361-25-041275
Event type: other_material
Sentiment:  positive
Materiality: 0.85
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Galectin Therapeutics presents NAVIGATE trial: belapectin reduces varices, biomarkers improve
--------------------------------------------------------------------------------

- Belapectin 2 mg/kg reduced new varices vs placebo across all ELF risk categories at 18 months; in highest risk (ELF>11.3): 22.7% vs 42.9%.
- Pro-C3 biomarker showed >50% reduction from baseline at 18 months with belapectin 2 mg/kg vs placebo (mean -6.4 vs -4.5 ng/mL).
- Higher proportion of belapectin 2 mg/kg patients achieved ≥20% reduction in YKL-40 (33.8% vs 23.1%); fewer had ≥20% PRO-C4 increase (3% vs 13%).
- At 36 months, cumulative new varices incidence 12.4% (belapectin 2 mg/kg) vs 23.4% (placebo), sustained benefit.
- Safety profile encouraging; adverse events and serious adverse events comparable to placebo, no drug-related SAEs.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125041275/0001140361-25-041275-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1133416/000114036125041275/ny20058530x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-25-041275

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer